Thioperamide induces CD4^+ CD25^+ Foxp3^+ regulatory T lymphocytes in the lung mucosa of allergic mice through its action on dendritic cells

Maria Marta Amaral1*
Carolina A Alvarez1*
Cecilia Langellotti2
Carolina Jancic1
Gabriela Salamone1
Jorge Geffner1
Mónica Vermeulen1

1Institute of Hematologic Research, National Academy of Medicine, Buenos Aires, Argentina; 2Institute of Virology, CICVyA, INTA, Castelar, Argentina

*Authors contributed equally to this work

Background: Histamine is an important mediator in the development of allergic reactions. The biological effects of histamine are mediated through four histaminergic receptors. In recent years, an important role has been assigned to the proinflammatory functions of histamine regarding the H4 receptor. Previously, we have demonstrated that injection of immature dendritic cells treated with histamine into allergic mice promotes an increase in CD8^+ Tc2 lymphocytes, which are involved in the worsening of allergy symptoms during the chronic phase of the disease. The aim of this study was to evaluate the role of the H3/H4 receptor antagonist, thioperamide, in allergy.

Methods: Ovalbumin-allergized mice and nonallergized mice were injected with phosphate-buffered saline, dendritic cells, or thioperamide-treated dendritic cells. After treatment, the lungs of the mice were obtained and analyzed for changes in the populations of dendritic cells and T lymphocytes, as well as the expression of H and H4 receptors in mononuclear lung cells.

Results: We found an increase in regulatory T cells in the lungs of allergic mice intratracheally injected with dendritic cells which had their H3/H4 receptors blocked with thioperamide. We also found an increase in the production of interleukin-10 by dendritic cells of the lung. Finally, we observed a decrease in serum levels of specific anti-IgE and a reduction of eosinophils in bronchoalveolar lavage from allergic mice.

Conclusion: Thioperamide induces a significant improvement in symptoms of allergic reaction perhaps via induction of regulatory T lymphocytes. These findings may become relevant in the understanding of type 1 hypersensitivity reactions.

Keywords: dendritic cells, regulatory T lymphocytes, thioperamide, histamine, allergy

Introduction

Dendritic cells are antigen-presenting cells with a unique ability to initiate the adaptive response by activating naive T lymphocytes. However, these cells are not only able to prime immune responses, but also induce self-tolerance.1,2 The recognition of inflammatory stimuli or pathogens in the periphery imposes several changes in dendritic cells, leading to their maturation. These changes enable dendritic cells to activate T lymphocytes and to determine their profile of polarization.3,4

Histamine plays a central role in the regulation of both inflammatory and immune responses. It is also able to modulate the function of dendritic cells. Histamine stimulates the chemotaxis of immature dendritic cells and promotes differentiation of T CD4^+ lymphocytes into a Th2 profile.5 In addition, in immature dendritic cells from mice, histamine induces the cross-presentation of soluble antigens, such as ovalbumin, acting through H3/H4 receptors.6 Recently, we found a higher recruitment of CD11c^+/CD8^+ dendritic cells and Tc2 type T CD8^+ cells in the lungs of allergic mice...
receiving dendritic cells treated with histamine and pulsed with ovalbumin. In addition, these mice showed increased levels of serum-specific IgE antibodies and a more persistent presence of eosinophils in bronchoalveolar lavage compared with mice treated with ovalbumin-pulsed control dendritic cells. This suggests that histamine may influence the severity of allergies by acting on dendritic cells.

Allergic diseases, including conjunctivitis, allergic rhinitis, asthma, and atopic dermatitis, are inflammatory disorders in which susceptible individuals respond by producing allergen-specific Th2 lymphocytes. Histamine is one of the most important mediators of allergy and inflammation. Although its effects are mediated via four receptors, signaling through H1R seems to play a central role in the induction of allergy, but the use of antagonists of this receptor, like ketotifen, did not prove to be effective in most of these pathologies because the symptoms did not disappear completely.

It was shown that the H4 receptor plays an essential role in inflammatory pathologies. H4R was involved in the amplification of allergic symptoms as well as the maintenance of chronic inflammation. In this study, we evaluated the effect of injection of dendritic cells pretreated with thioperamide and pulsed with ovalbumin in allergic mice in vitro. Interestingly, we found a significant increase in CD4+ CD25+ FOXP3+ lymphocytes, as well as increased levels of interleukin-10 in lung dendritic cells of allergic mice. In addition, the levels of specific anti-IgE antibodies as the percentages of eosinophils are decreased. Therefore, H3/H4 receptors would be central to the induction of chronic inflammatory responses. Future studies may determine whether the use of antagonists of these receptors could offer an alternative in the treatment of inflammatory disorders through the induction of a regulatory profile.

Methods
Mice
All experiments were carried out using two-month-old virgin female BALB/c mice raised at the National Academy of Medicine, Buenos Aires, Argentina. They were housed as 4–6 animals per cage and kept at 20°C ± 2°C on an automatic 12-hour light-dark schedule. Animal care was in accordance with institutional guidelines.

Sensitization and challenge with ovalbumin
Mice (4–6 per experiment) were sensitized using a standard protocol, as described previously. Briefly, mice were injected intraperitoneally with 20 µg of ovalbumin (Grade V, Sigma-Aldrich, St Louis, MO) in 2 mg of aluminum hydroxide at days 0 and 7. Control mice received a saline injection instead of ovalbumin/aluminum hydroxide solution (Sigma, St Louis, MO). On day 14, sensitized mice were challenged intranasally with 50 µL of phosphate-buffered saline containing 3% ovalbumin for five days. Control mice were instilled with phosphate-buffered saline.

Dendritic cell generation from bone marrow cultures
The procedure used to obtain dendritic cells was performed as described by Inaba et al, with minor modifications. Briefly, bone marrow was flushed from the long bones of the limbs using 2 mL of RPMI 1640 medium (Invitrogen, Carlsbad, CA) with a syringe and 25-gauge needle. Red cells were lysed with ammonium chloride. After washing, the cells were suspended at a concentration of 1.5 × 10⁷ cells/mL in 70% RPMI 1640 medium supplemented with 10% fetal calf serum, and 5.5 × 10⁻⁵ mercaptoethanol (complete medium [Gibco, Buenos Aires, Argentina]) from Sigma and 30% J588-GM cell line supernatant. The cultures were fed every two days by gently swirling the plates, aspirating 50% of the medium, and adding back fresh medium with J588-GM cell line supernatant. At day 9 of the culture, more than 80% of the harvested cells expressed major histocompatibility class (MHC) II, CD40 and CD11c, but not GR-1 (not shown).

Intratracheal injection of dendritic cells
Dendritic cells obtained from bone marrow precursors were incubated in the absence or presence of thioperamide 100 µM (dendritic cells and thioperamide-pretreated dendritic cells, respectively) for 30 minutes at 37°C. The cells were then incubated for three hours at 37°C in the presence or absence of ovalbumin 100 µg/mL. Finally, the dendritic cells were washed and injected intratracheally into BALB/c mice after intranasal challenge of sensitized mice with ovalbumin. For this purpose, the mice were anesthetized with pentobarbital sodium (Nembutal, [Abbott Laboratories, Buenos Aires, Argentina]) (2% v/v in phosphate-buffered saline), and 100 µL of phosphate-buffered saline, dendritic cells, or thioperamide-pretreated dendritic cells (5 × 10⁵ cells) were injected.

Treatment of lung tissues to obtain a cellular suspension
The lungs were cut into small pieces and treated with Type I collagenase 250 U/mL (Roche, Buenos Aires, Argentina) for 30 minutes at 37°C. At the end of the incubation time, the reaction was stopped by addition of phosphate-buffered saline.
supplemented with 5% fetal calf serum. Subsequently, the fragments were incubated with DNase I 50 U/mL (Invitrogen, Buenos Aires, Argentina) for 40 minutes at 37°C. Finally, the cell suspensions were collected through a gauze mesh and washed with cold phosphate-buffered saline. For the analysis of H3 and H4 receptors, lung suspensions were seeded in a Ficoll-Hypaque (Amersham Biosciences, Buenos Aires, Argentina) gradient and centrifuged for 40 minutes at 1600 rpm to obtain the mononuclear cell monolayer.

Bronchoalveolar lavage
At 15 or 30 days, after treatment of the allergic mice with phosphate-buffered saline, dendritic cells, or thioperamide-pretreated dendritic cells, the lungs were washed via a tracheal tube with phosphate-buffered saline. Cells were washed and leukocyte counts were determined by optical microscopy. Cytospin slides were stained with toluidine to determine the percentages of eosinophils in bronchoalveolar lavage.

Flow cytometry
Cells were stained for cell surface markers with the following monoclonal antibodies: anti-CD11c, anti-CD40, anti-CD86, anti-MHC class II, anti-CD4+, anti-CD25+, and anti-GR1 (FITC, PE or PERCP, Pharmingen, San Diego, CA). The staining was analyzed by flow cytometry on FACScan using Cellquest software (BD Biosciences, Buenos Aires, Argentina).

Analysis of serum levels of IgE antibodies directed to ovalbumin
Serum samples were obtained from the mice at the end of the experiments by cardiac puncture. Ovalbumin-specific IgE antibodies were determined using plates coated overnight with 1 µg/mL ovalbumin in sodium carbonate buffer (pH 9.5, Sigma-Aldrich, St Louis, MO). Plates were pretreated with Tween 0.5% in phosphate-buffered saline supplemented with 1% bovine serum albumin for two hours at room temperature. Serial dilutions of sera were added and, after two hours, the plates were washed three times with Tween 0.5% in phosphate-buffered saline, and an appropriate dilution of biotinylated detection antibody (rat anti-mouse IgE, BD Pharmingen, Buenos Aires, Argentina) was added for one hour. The stained cells were washed with saponin (0.1% in phosphate-buffered saline). The cells were then incubated with FITC-conjugated anti-FOXP3 in phosphate-buffered saline 0.5% bovine serum albumin or a similarly labeled isotype-matched control antibody for 30 minutes. Antibodies against FOXP3 was purchased from BD Pharmingen. Cells were subsequently washed with phosphate-buffered saline and stained for surface cell markers with the monoclonal antibodies anti-CD4+ and anti-CD25+. The stained cells were washed with saponin buffer twice and resuspended in isoflow. The staining was analyzed by flow cytometry on FACScan using Cellquest software.

Interleukin-10 production
Dendritic cells purified from the lungs were stimulated for 18 hours with ovalbumin 10 ng/mL. Interleukin-10 production was then analyzed by enzyme-linked immunosorbent assay (eBioscience, San Diego, CA) in the supernatants of CD11c+ cells (1.5 × 10⁵ cells/200 µL cultured for 18 hours).

Confocal microscopy
Mononuclear cells from lung tissue of BALB/c mice were used for receptor expression analysis, and were fixed with a mixture of 2% paraformaldehyde (Merck, Germany) and 0.125% glutaraldehyde (Electron Microscopy Science, Hartfield, PA) in 0.2 M phosphate buffer at pH 7.4 for two hours at room temperature. Fixed cells were processed for ultrathin cryosectioning, immunogold-labeled and contrasted as described previously. Cells (5 × 10⁵) were incubated for 30 minutes at room temperature. Then cells were fixed in 4% paraformaldehyde for 10 minutes at 4°C, after which the cells were treated with 0.1 M of glycine to block aldehyde groups. Cells were washed with cold medium and fixed as above. At the optimal antibody concentrations, no background labeling of the nucleus and mitochondria was detected (data not shown). Sections were observed and photographed under a Philips CM120 electron microscope (FEI Company, Eindhoven, The Netherlands). Images were acquired using the ITEM program. The quantification of H3 and H4 receptor expression was performed using the Image J program.
T lymphocyte proliferation assay

For the autologous Ag-specific proliferation assay, 2.5 × 10⁵ T lymphocytes from the lungs of BALB/c mice previously allergized were cocultured with 5 × 10⁴ purified dendritic cells from BALB/c mice that were treated in vitro with ovalbumin. At 72 hours, cells were pulsed with [³H] thymidine (1 µCi/well, DuPont-New England Biolabs, Boston, MA). Then cells were harvested using a semiautomatic harvester (Skatron Instruments), and the amount of [³H]thymidine incorporation was determined in a Wallac 1414 Winspectral beta scintillation counter (PerkinElmer). Unspecific T cell proliferation was measured by stimulation of 2.5 × 10⁵ splenocytes with 1 µg/mL lipopolysaccharide (Sigma-Aldrich) for 96 hours.

Statistical analysis

Statistically significant differences between means were assessed by the Student’s t-test. P < 0.05 was taken as indicating statistical significance.

Results

Previously we have demonstrated that histamine increases the cross-presentation of extracellular antigens by dendritic cells acting through H3R/H4R. Moreover, we found in a mouse model of allergic airway inflammation that injection of dendritic cells treated with histamine in vitro increases recruitment of Tc2 CD8+ T cells in the lungs of allergic mice, suggesting an effect on the chronicity of the process. In light of these findings, we decided to investigate the role of H4/H3 receptors in the development of the allergic process. Airway inflammation was induced in BALB/c mice by intraperitoneal injection of ovalbumin in aluminum hydroxide followed by challenge with aerosolized ovalbumin, as described in the Methods section. Dendritic cells differentiated from bone marrow precursors were incubated for 30 minutes at 37°C with thioperamide (100 µM), an antagonist of H3R/H4R, or phosphate-buffered saline. Either dendritic cells or thioperamide-pretreated dendritic cells were then pulsed with ovalbumin 10 µg/mL for three hours at 37°C and, after washing, the cells (5 × 10⁴) were intratracheally injected into mice after five days of challenge with aerosolized ovalbumin. Control mice were inoculated intratracheally with phosphate-buffered saline instead of dendritic cells. Figure 1A shows the phenotype of the injected dendritic cells. Incubation with ovalbumin did not change the maturity status of the dendritic cells and, as shown, expression of CD40, CD86, and MHC class II was not affected.

Two weeks later, we obtained the population of T lymphocytes by treatment of lung cells suspensions with a PanT antibody (anti-CD3) and subsequent purification through an affinity column. Finally, we analyzed regulatory T lymphocytes by cytometry. In Figure 1B and C, we found as already described that injection of immature dendritic cells induced an increase in regulatory T cells (CD4+ CD25+ FOXP3+) in the lungs of allergic mice. Interestingly, in the allergic mice that received dendritic cells with receptors H3 and H4 blocked by thioperamide, we found high recruitment of regulatory T cells in the lungs, which was significantly greater than that observed for untreated dendritic cells (40%). We noted that while the percentage of CD4+ T lymphocytes decreased with both treatments, the population of regulatory T cells was even greater, perhaps as a result of inhibition of the effector cell population.

It is known that plasmacytoid and lymphoid dendritic cells are able to induce T regulatory cells in the lung, so we decided to evaluate whether use of thioperamide affects a particular subset of dendritic cells in the lungs of allergic mice. Dendritic cells were purified from lung suspensions from allergic mice that had been inoculated with ovalbumin-pulsed dendritic cells or thioperamide-pretreated dendritic cells, by positive selection, using magnetic beads attached to anti-CD11c. As shown in Figure 2A and B, lymphoid dendritic cells (CD11c+ CD8α+) were increased both by dendritic cells and thioperamide-pretreated dendritic cells, but no significant differences between dendritic cells and thioperamide-pretreated dendritic cells were observed, so we can assume that the increase was at the expense of dendritic cells alone. Moreover, we observed no difference between treatments for the plasmacytoid dendritic cell subset (Figure 2C and D).

Considering that induction of tolerance by dendritic cells is associated mainly with release of interleukin-10, we also investigated this issue. As shown in Figure 3A, we found that CD11c (+) dendritic cells isolated from the lung tissue of mice treated with thioperamide-pretreated dendritic cells released higher levels of interleukin-10 compared with CD11c (+) cells isolated from the lung tissue of mice that received untreated dendritic cells. This result may reflect that the blockade of H3/H4 receptors, inhibits the cellular response through the induction of regulatory T cells in the lungs of allergic mice, could be a mechanism mediated in part, by the interleukin-10 secreted from thioperamide-pretreated dendritic cells. We investigated this possibility two weeks after injection of allergic mice with phosphate-buffered saline, dendritic cells, or thioperamide-pretreated dendritic cells, by purifying CD11c+ cells from lungs and coculturing them with autologous T lymphocytes from allergized mice. As shown in Figure 3B, thioperamide-stimulated dendritic
cells did not induce proliferation of T cells, and a ratio of 5:1 (effector:target) strongly inhibited this action.

In order to determine whether H3/H4 receptor blockade leads to an improvement in allergy symptoms, we then measured serum levels of ovalbumin-IgE antibodies and the presence of eosinophils in bronchoalveolar lavage from allergic mice 15 days after intratracheal injection. As shown in Figure 4A and B, both of these parameters were significantly decreased in allergic mice inoculated with ovalbumin-pulsed thioperamide-pretreated dendritic cells compared with the allergic controls.

In light of these results, we were interested in investigating whether these receptors, which are known to be implicated in the allergic process, are represented in the lung tissue of allergic mice. Therefore, we analyzed the expression of H3R and H4R in mononuclear lung cells of allergic mice by confocal microscopy (see Methods section) using positive control brain tissue (for H3R) and bone marrow precursors (for H4R). We used specific antibodies against these receptors and membrane markers associated with dendritic cells and macrophages, such as CD11c and CD11b. As shown in Figure 5B, we found that while expression of H4R was associated with cells that express CD11c and CD11b, H3R showed only weak expression in the fraction corresponding to mononuclear lung cells not associated with expression of CD11c and CD11b markers (Figure 5A and B).

**Discussion**

It has been demonstrated in a mouse model of food allergy that subcutaneous administration of synthetic peptides comprising immunodominant T cell determinants of ovalbumin to sensitized BALB/c mice decreases allergy symptoms. This therapy reduced the hypersensitivity reaction, ie, serum histamine and ovalbumin-specific IgE levels. Interestingly, an increase in mRNA expression of both regulatory molecules, TGF-β and FOXP3, was detected in intestinal tissues, contributing to the suppressive effect to the allergy. In our research, we showed in a widely accepted mouse model of...
Amaral et al

Journal of Asthma and Allergy 2011:4

Figure 2 Thioperamide-pretreated dendritic cells stimulate recruitment of CD11c+ CD8α+ dendritic cells in the lung tissue of allergic mice. Dendritic cells pretreated or not pretreated with thioperamide 100 μM and pulsed with ovalbumin were intratracheally inoculated (5 × 10^5 cells/allergized mouse). After 15 days, the mice were sacrificed and the lungs were processed. Lung cell suspensions were enriched using antibodies directed to CD11c coupled with magnetic beads. Isolated cells were analyzed for the expression of CD11c, B220, GR1, and CD8α using specific antibodies labeled with PE, PerCP, and FITC. (A) Lymphoid dendritic cells (CD11c+ CD8α+) and (C) plasmacytoid dendritic cells (CD11c+ B220+). Results are expressed as the mean ± standard error of the mean of six experiments. (B) and (D) show representative experiments in myeloid and plasmacytoid dendritic cells, respectively.

Note: **P < 0.01 versus controls.

Figure 3 Thioperamide induces interleukin-10 production in dendritic cells and inhibition of T lymphocyte proliferation. We obtained a population of lung dendritic cells by treatment of cell suspensions with anti-CD11c and later purification through an affinity column. Production of interleukin-10 was analyzed in the supernatants of CD11c+ cells (1.5 × 10^5 cells/200 μL cultured for 18 hours) by enzyme-linked immunosorbent assay. (A) Bar graph representing the arithmetic mean of interleukin-10 concentration (pg/mL) ± standard error of the mean, n = 5. *P ≤ 0.05 for phosphate-buffered saline versus dendritic cells versus thioperamide-pretreated dendritic cells. To investigate for differences in T lymphocyte stimulatory ability of lung dendritic cells, we purified lung dendritic cells from treated allergic mice after 12 days. Cells were washed and cocultured with autologous lymphocytes from allergic mice (5 × 10^4 dendritic cells/well versus 2.5 × 10^5 splenocytes/well). Dendritic cells stimulated for 48 hours with lipopolysaccharides were included as a positive control. (B) T cell proliferation was measured 72 hours after starting cocultures by [3H]thymidine incorporation. Data are expressed as the mean [3H]thymidine incorporation and are representative of five independent experiments. *P < 0.05. (C) Forty-eight hours after starting coculture, the supernatants were collected and analyzed for interleukin-10 production by quantitative enzyme-linked immunosorbent assay.

Note: Mean concentration values are expressed as pg/mL. *P < 0.05.
acute airway inflammation in response to ovalbumin, that intratracheal injection of dendritic cells with H3R/H4R blocked by thioperamide increased the proportions of CD4+ CD25+ FOXP3+ cells in the lungs of allergic mice, demonstrating a role of endogenous histamine in the modulation of regulatory T cells. It should be noted that dendritic cells constitutively produce histamine, although the presence of inflammatory stimuli strongly increases the secretory capacity of dendritic cells, suggesting that histamine could play an autocrine role during genesis of the inflammatory response.

Functionally, this model is divided in two phases, ie, sensitization and provocation. In the sensitization phase, the experimental allergen, ie, ovalbumin, is taken up by dendritic cells that induce a polarized Th2 response and IgE production. Re-exposure to ovalbumin is referred to as provocation that induces the acute allergic reaction. It is now widely accepted that recruitment of CD8+ Tc2 cells is crucial in maintaining airway hyperresponsiveness and eosinophilia in the later phase of the asthma process. Massive amounts of histamine are released in allergic reactions like asthma, rhinitis, and conjunctivitis. In this sense, the published research supports the essential role of this biogenic amine in the inflammatory reaction, acting through four histamine receptors, referred to as H1R, H2R, H3R, and H4R.

We have previously demonstrated in vitro that histamine increases the cross-presentation of soluble ovalbumin by immature murine dendritic cells. In a recent paper, we also showed that histamine acting on dendritic cells can favor the recruitment of TCD8+ cells in lung tissue of allergic mice, indicating a likely role of this amine in the chronic phase. This was demonstrated by the fact that mice with histamine-treated dendritic cells showed increased levels of serum-specific IgE antibodies directed to ovalbumin, and a more persistent presence of eosinophils in bronchoalveolar lavage fluid compared with mice treated with ovalbumin-pulsed control dendritic cells. An interesting finding was that blocking of H3R/H4R on dendritic cells reduced the numbers of eosinophils and specific IgE antibodies in allergic mice, as reported by Dunford et al using an H4R-selective antagonist, JNJ 7777120 or H4R-deficient mice. However, the point of balance between dendritic cells and T cells at which symptom improvement occurs is not clearly defined. When we analyzed regulatory T cells in the lungs of allergic mice, we found a greater increase in CD4+/FOXP3+ cells, indicating that H4R blockade on dendritic cells with thioperamide caused an improvement in asthmatic symptoms by induction of T regulatory cells which suppress the effector response via production of interleukin-10. It has been shown that activation of regulatory T cells in allergy not only leads to suppression of lymphocyte proliferation, but also downregulates production of specific IgE antibodies and reduces inflammation by inhibiting the activity of inflammatory cells, including eosinophils, basophils, and mast cells. In addition, the amounts required for this function are low, considering that, once specifically activated, their suppressor function operates on all effector lymphocytes independently of their specificity.

Yang et al showed that increased mRNA expression of transforming growth factor beta and FOXP3 in intestinal tissues is consistent with low serum histamine levels. In line with this, our results reinforce the idea that endogenous histamine acting on dendritic cells negatively regulates
induction of Treg cells in the lung tissue of allergic mice, being dependent on H4R for this action. Morgan et al studied a mouse model of airway hypersensitivity and demonstrated that intratracheal administration of 4MeHA, an H4R-selective ligand, is associated with a reduction in asthma-like symptoms attributed to accumulation of FOXP3+ T cells in the lung. These authors assumed an anti-inflammatory function of H4R. However, before discovery of H4R, 4MeHA was used as a specific ligand for H2R, so it is possible that the anti-inflammatory effects observed were due to activation of H2R rather than H4R. In rhinitis or conjunctivitis, the H1R antagonist is effective in controlling clinical symptoms, but is not relevant in asthma. This may be explained by the fact that asthma has a multifactorial pathogenesis. In this regard, development of a Th2 response is essential for sensitization and the early inflammatory response, but the chronicity of the process depends on recruitment of CD8+ T cells. Our results and those of other research groups reinforce the idea that the action of histamine on dendritic cells has a proinflammatory role. In this way, H4R blockade or deficiency has been effective in reducing asthma symptoms in several studies, perhaps through an increase in regulatory T cells. Forward et al investigated the consequences of mast cell and regulatory CD4+ CD25+ T cell interaction, and concluded that histamine signaling via H1 receptors leads to reduction in the suppressor function of these regulatory T cells, and this function is restored when histamine levels decrease. Thus, local histamine produced by mast cells and dendritic cells could modulate the development of inflammatory reactions at different levels, ie, by acting via H1R on innate cells present in tissues and by maintenance of the inflammatory response via H4R on dendritic cells.

An interesting observation was that expression of the H4 receptor is restricted to CD11c+ lung cells. Recently, Lundberg et al showed that blockade of H4R in monocyte-derived dendritic cells from allergic donors inhibited allergen-specific T cell responses. Given that alveolar macrophages and dendritic cells are the most abundant cell populations expressing CD11c+ in the lung mucosa, and considering that dendritic cells are potential targets in allergic therapy because they define polarization of T lymphocytes under the influence of microenvironment, it is possible that use of H4R antagonists may enable more effective treatment of allergic diseases.

**Conclusion**

We conclude that treatment of dendritic cells with thioperamide, an H3/H4 receptor antagonist, increases CD4+ CD25+ FOXP3+
regulatory T cells in the lungs of allergic mice, suggesting that endogenous histamine exerts autocrine control of dendritic cells during the inflammatory response. Considering that mucosal dendritic cells in the lung express the H4 receptor, we believe that its blockade may favor the induction of a beneficial anti-inflammatory response to counteract allergic effects.

Acknowledgments
This work was supported by grants from the Consejo Nacional de Investigaciones Científicas y Técnicas and the Agencia Nacional de Promoción Científica y Tecnológica, Argentina. We thank Beatriz Loria and Edith Mabel Horvat for their technical assistance with this research.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Joffre O, Nolte MA, Sporri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. *Immunrol Rev.* 2009;227(1):234–247.
2. Carbone FR, Belz GT, Heath WR. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. *Trends Immunol.* 2004;25(12):655–658.
3. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. *Semin Immunol.* 2004;16(1):27–34.
4. Sabatté J, Maggini J, Nahmod K, et al. Interplay of pathogens, cytokines and other stress signals in the regulation of dendritic cell function. *Cytokine Growth Factor Rev.* 2007;18(1–2):5–17.
5. Gutzmer R, Diestel C, Mommert S, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. *J Immunol.* 2005;174(9):5224–5232.
6. Bäumer W, Wendorff S, Gutzmer R, et al. Histamine H4 receptors modulate dendritic cell migration through skin immunomodulatory role of histamine. *Allergy.* 2008;63(10):1387–1394.
7. Amaral MM, Alvarez C, Langelott C, Geffner J, Vermeulen M. Histamine-treated dendritic cells improve recruitment of type 2 CD8 T cells in the lungs of allergic mice. *Immunology.* 2010;130(4):589–596.
8. Kay AB. Overview of allergy and allergic diseases: with a view to the future. *Br Med Bull.* 2000;56(4):843–864.
9. Hawrylowicz C, Ryanna K. Asthma and allergy: the early beginnings. *Nat Med.* 2010;16(3):274–275.
10. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. *Eur J Pharmacol.* 2006;533(1–3):69–76.
11. Phan H, Moelter ML, Nahata MC. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. *Drugs.* 2009;69(18):2541–2576.
12. Akdis CA. Allergy and hypersensitivity: mechanisms of allergic disease. *Curr Opin Immunol.* 2006;18(6):718–726.
13. Jablonski JW, Carruthers NJ, Thurmond RL. The histamine H4 receptor and potential therapeutic uses for H4 ligands. *Mini Rev Med Chem.* 2004;4(9):993–1000.
14. Lloyd CM, Gonzalez JA, Coyle AJ, Gutierrez-Ramos JC. Mouse models of allergic airway disease. *Adv Immunol.* 2001;77:263–273.
15. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med.* 1992;176(6):1693–1697.
16. Vermeulen M, Giordano M, Trevani AS, et al. Acidosis improves uptake of antigens and MHC I-restricted presentation by dendritic cells. *J Immunol.* 2004;172(5):3196–3199.
17. Jancic C, Savina A, Wasmieier C, et al. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. *Nat Cell Biol.* 2007;9(4):367–378.
18. Amaral MM, Davio C, Ceballos A, et al. Histamine improves antigen uptake and cross-presentation by dendritic cells. *J Immunol.* 2007;179(6):3425–3433.
19. Huang H, Dawicki W, Zhang X, Town J, Gordon JR. Tolerogenic dendritic cells induce CD4+ CD25+ Foxp3+ regulatory T cell differentiation from CD4+CD25+Foxp3- effector T cells. *J Immunol.* 2010;185(9):5003–5010.
20. Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. *Eur J Immunol.* 2010;40(10):2667–2676.
21. Langlois RA, Legge KL. Respiratory dendritic cells: mediators of tolerance and immunity. *Immunol Res.* 2007;39(1–3):128–145.
22. Wikstrom ME, Stumbles PA. Mouse respiratory tract dendritic cell subsets and the immunological fate of inhaled antigens. *Immunol Cell Biol.* 2007;85(3):182–188.
23. GeurtsvanKessel CH, Lambrecht BN. Division of labor between dendritic cell subsets of the lung. *Mucosal Immunol.* 2007;1(6):442–450.
24. Yang M, Yang C, Mine Y. Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3 and transforming growth factor-beta-associated mechanisms. *Clin Exp Allergy.* 2010;40(4):668–678.
25. Dunford PJ, O’Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. *J Immunol.* 2006;176(11):7062–7070.
26. Shin YS, Takeda K, Gelfand EW. Understanding asthma using animal models. *Allergy Asthma Immunol Res.* 2009;1(1):10–18.
27. Takeda K, Gelfand EW. Mouse models of allergic diseases. *Curr Opin Crit Care.* 2009;21(6):660–665.
28. Gelfand EW, Dakhama A. CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. *J Allergy Clin Immunol.* 2006;117(3):577–582.
29. Miyahara N, Takeda K, Kodama T, et al. Contribution of antigen-primed CD8+ T cells to the development of airway hyperresponsiveness and inflammation is associated with IL-2. *J Immunol.* 2004;172(4):2549–2549.
30. Yeh YC, Xie L, Langdon JM, et al. The effects of overexpression of histamine releasing factor (HRF) in a transgenic mouse model. *PLoS One.* 2010;5(6):e11077.
31. Cowden JM, Riley JP, Ma JY, Thurmond RL, Dunford PJ. Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. *Respir Res.* 2010;11:86.
32. Neumann D, Beermann S, Seifert R. Does the histamine H4 receptor have a pro- or anti-inflammatory role in murine bronchial asthma? *Respirology.* 2010;15(4):217–223.
33. Braga M, Quechua C, Cavallucci E, et al. T regulatory cells in allergy. *Int J Immunopathol Pharmacol.* 2011;24(1 Suppl):S55–S65.
34. Ozdemir C, Akdis M, Akdis CA. T regulatory cells and their counterparts: masters of immune regulation. *Clin Exp Allergy.* 2009;39(5):626–639.
35. Morgan RK, McAllister B, Cross L, et al. Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic asthma in a murine model. *J Immunol.* 2007;178(12):8081–8089.
36. Durant GJ, Ganelin CR, Parsons ME. Chemical differentiation of histamine H1- and H2-receptor agonists. *J Med Chem.* 1975;18(9):905–909.
37. Mitsuhashi M, Mitsuhashi T, Payan D. Multiple signaling pathways of histamine H2 receptors. Identification of an H2 receptor dependent Ca2+ mobilization pathway in human HL-60 promyelocytic leukemia cells. *J Biol Chem.* 1989;264(31):18356–18362.
38. Forward NA, Furlong SJ, Yang Y, Lin TJ, Hoskin DW. Mast cells down-regulate CD4+CD25+T regulatory cell suppressor function via histamine H1 receptor interaction. *J Immunol*. 2009;183(5):3014–3022.

39. Lundberg K, Broos S, Greiff L, Borrebaeck CA, Lindstedt M. Histamine H(4) receptor antagonism inhibits allergen-specific T-cell responses mediated by human dendritic cells. *Eur J Pharmacol*. 2010;651(1–3):197–204.

40. Lambrecht BN, Hammad H. Biology of lung dendritic cells at the origin of asthma. *Immunity*. 2009;31(3):412–424.